Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes

Abstract Drug repurposing is a feasible strategy for the development of novel therapeutic applications. However, its potential use for oral treatments and impact on host microbiota remain underexplored. Here, we assessed the influences of topical oral applications of a repurposed FDA-approved drug,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aurea Simon-Soro, Dongyeop Kim, Yong Li, Yuan Liu, Tatsuro Ito, Kenneth R. Sims, Danielle S. W. Benoit, Kyle Bittinger, Hyun Koo
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Microbial ecology QR100-130
Acceso en línea:	https://doaj.org/article/b667744803a34606af4ae636325d7c88
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b667744803a34606af4ae636325d7c88
record_format	dspace
spelling	oai:doaj.org-article:b667744803a34606af4ae636325d7c882021-12-02T15:23:49ZImpact of the repurposed drug thonzonium bromide on host oral-gut microbiomes10.1038/s41522-020-00181-52055-5008https://doaj.org/article/b667744803a34606af4ae636325d7c882021-01-01T00:00:00Zhttps://doi.org/10.1038/s41522-020-00181-5https://doaj.org/toc/2055-5008Abstract Drug repurposing is a feasible strategy for the development of novel therapeutic applications. However, its potential use for oral treatments and impact on host microbiota remain underexplored. Here, we assessed the influences of topical oral applications of a repurposed FDA-approved drug, thonzonium bromide, on gastrointestinal microbiomes and host tissues in a rat model of dental caries designed to reduce cross-contamination associated with coprophagy. Using this model, we recapitulated the body site microbiota that mirrored the human microbiome profile. Oral microbiota was perturbed by the treatments with specific disruption of Rothia and Veillonella without affecting the global composition of the fecal microbiome. However, disturbances in the oral-gut microbial interactions were identified using nestedness and machine learning, showing increased sharing of oral taxon Sutterella in the gut microbiota. Host-tissue analyses revealed caries reduction on teeth by thonzonium bromide without cytotoxic effects, indicating bioactivity and biocompatibility when used orally. Altogether, we demonstrate how an oral treatment using a repurposed drug causes localized microbial disturbances and therapeutic effects while promoting turnover of specific oral species in the lower gut in vivo.Aurea Simon-SoroDongyeop KimYong LiYuan LiuTatsuro ItoKenneth R. SimsDanielle S. W. BenoitKyle BittingerHyun KooNature PortfolioarticleMicrobial ecologyQR100-130ENnpj Biofilms and Microbiomes, Vol 7, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Microbial ecology QR100-130
spellingShingle	Microbial ecology QR100-130 Aurea Simon-Soro Dongyeop Kim Yong Li Yuan Liu Tatsuro Ito Kenneth R. Sims Danielle S. W. Benoit Kyle Bittinger Hyun Koo Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes
description	Abstract Drug repurposing is a feasible strategy for the development of novel therapeutic applications. However, its potential use for oral treatments and impact on host microbiota remain underexplored. Here, we assessed the influences of topical oral applications of a repurposed FDA-approved drug, thonzonium bromide, on gastrointestinal microbiomes and host tissues in a rat model of dental caries designed to reduce cross-contamination associated with coprophagy. Using this model, we recapitulated the body site microbiota that mirrored the human microbiome profile. Oral microbiota was perturbed by the treatments with specific disruption of Rothia and Veillonella without affecting the global composition of the fecal microbiome. However, disturbances in the oral-gut microbial interactions were identified using nestedness and machine learning, showing increased sharing of oral taxon Sutterella in the gut microbiota. Host-tissue analyses revealed caries reduction on teeth by thonzonium bromide without cytotoxic effects, indicating bioactivity and biocompatibility when used orally. Altogether, we demonstrate how an oral treatment using a repurposed drug causes localized microbial disturbances and therapeutic effects while promoting turnover of specific oral species in the lower gut in vivo.
format	article
author	Aurea Simon-Soro Dongyeop Kim Yong Li Yuan Liu Tatsuro Ito Kenneth R. Sims Danielle S. W. Benoit Kyle Bittinger Hyun Koo
author_facet	Aurea Simon-Soro Dongyeop Kim Yong Li Yuan Liu Tatsuro Ito Kenneth R. Sims Danielle S. W. Benoit Kyle Bittinger Hyun Koo
author_sort	Aurea Simon-Soro
title	Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes
title_short	Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes
title_full	Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes
title_fullStr	Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes
title_full_unstemmed	Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes
title_sort	impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b667744803a34606af4ae636325d7c88
work_keys_str_mv	AT aureasimonsoro impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT dongyeopkim impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT yongli impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT yuanliu impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT tatsuroito impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT kennethrsims impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT danielleswbenoit impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT kylebittinger impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes AT hyunkoo impactoftherepurposeddrugthonzoniumbromideonhostoralgutmicrobiomes
_version_	1718387287435247616

Impact of the repurposed drug thonzonium bromide on host oral-gut microbiomes

Ejemplares similares